Less is known about long-term HD therapy and its effects on myocardial structure and function under the novel conditions: anemia and erythropoietin stimulating agents (ESA) therapy, chronic kidney disease–mineral bone disorder (CKD-MBD) and its treatment, fluid overload, novel blood pressure conditions, novel diet and metabolism conditions, and so on. Here, EPO is linked to chronic kidney disease.